Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05696652 · ClinicalTrials.gov registry record · NA

Identifying Markers of Exercise Training in Heart Failure

A NA study of Heart Failure, sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT05696652: Recruiting NA study of Heart Failure, sponsored by Stanford University.

NCT05696652 is a NA study of Heart Failure that is actively recruiting participants, run by Stanford University. The registered enrollment target is 90 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05696652, a NA study of Heart Failure, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The heart failure syndrome that occurs when the heart is too sick to properly do its job. One of the main symptoms is difficulty with exercise. One way to improve symptoms is to start patients in a 12 week exercise program called cardiac rehabilitation. Cardiac rehabilitation been shown to improve symptoms for heart failure patients. However, the investigators do not know exactly what exercise does to the molecules that make up the human body. If the investigators could answer this question, the investigators might find a whole new way to treat the symptoms of heart failure. Therefore the investigators want to know what molecules might be responsible for the benefits of exercise. The plan for this study is to measure the levels of thousands of proteins in blood samples which come from people with heart failure and see how those levels change after 12 weeks of cardiac rehabilitation, compared to the protein levels in patients whose cardiac rehabilitation is delayed until after the study period. If the investigators know the proteins that change with exercise, the investigators can then look to see if targeting these proteins with medicines can mimic the benefits of exercise. The long term goal of our work is to identify "exercise-in-a-pill" medicines that will help people with heart failure.

Primary Outcome

Patients will have proteomic profiling performed at baseline, prior to the intervention period, and again following the 12 week intervention. Proteomic profiling measures levels of \~3000 proteins in the blood, so the changes in the global proteome can be assessed after the intervention period.

Conditions Studied

Interventions

  • BEHAVIORAL Acute exercise
  • BEHAVIORAL Cardiac rehabilitation

Study Locations (1)

California

  • Stanford Health Care - Stanford

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-03-20
Est. Completion 2029-04-01
Phase NA
Stanford University

1,744 total trials

What NCT05696652 shows while recruiting

NCT05696652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Acute exercise is the first listed.

NCT05696652 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05696652 about?

NCT05696652 is a clinical study titled "Identifying Markers of Exercise Training in Heart Failure". The heart failure syndrome that occurs when the heart is too sick to properly do its job. One of the main symptoms is difficulty with exercise. One way to improve symptoms is to start patients in a 12 week exercise program called cardiac rehabilitation. Cardiac rehabilitation been shown to improve s...

What is the current status of trial NCT05696652?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2024-03-20. Estimated completion is 2029-04-01.

What conditions does trial NCT05696652 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT05696652?

The interventions under investigation include: Acute exercise (BEHAVIORAL), Cardiac rehabilitation (BEHAVIORAL).

Who is sponsoring clinical trial NCT05696652?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05696652 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05696652's enrollment target sits among peer trials

90 223rd of 397 higher than 175 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05696652, the US trial registry maintained by the National Library of Medicine. NCT05696652 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.